Labopharm Announces Intention To Delist From Nasdaq

Labopharm Inc. DDSS announced today its intention to delist its common shares from The Nasdaq Global Market as of the close of business on June 30, 2011. The Company's common shares will continue to be listed on the Toronto Stock Exchange. Following its delisting from Nasdaq, the Company intends to voluntarily terminate its public reporting obligations under the U.S. Securities Exchange Act as soon as possible. "The cost savings resulting from the Nasdaq delisting and termination of reporting obligations with the SEC in the U.S. will further preserve capital as the Company moves forward with its strategic review process," said Mark A. D'Souza, President and Chief Executive Officer.